Skip to main content

Anti-obesity Drugs Market Size worth USD 3,421.0 Million at 10.1% CAGR; Increasing Research for Developing Therapeutically Effective Drugs to Boost Demand in Europe

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, India, Feb. 15, 2021 (GLOBE NEWSWIRE) — The global anti-obesity drugs market size is set to grow significantly owing to the ever-increasing prevalence of obesity among the global population, observes Fortune Business Insights™ in its report. The market size was USD 1,520.2 million in 2019 and is anticipated to reach USD 3,421.0 million by 2027, exhibiting a CAGR of 10.1% during the forecast period.Healthcare Sector to Stumble amid COVID-19 PandemicThe healthcare sector has been the most active ever since the COVID-19 outbreak. While the pandemic has fast-tracked the development of the industry on a global scale, it has also brought numerous adversities upon the sector. These adversities include limited infrastructure in developing countries and the lack of preparedness in case of health emergencies. Key players are focusing on eliminating such challenges. At Fortune Business Insights, we are constantly analyzing the market conditions to offer the most effective solutions at your service.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/anti-obesity-drugs-market-104783
A List of Key Manufacturers Operating In the Market:•              Novo Nordisk (Denmark, Scandinavia)•              GlaxoSmithKline (Brentford, U.K)•              Vivus Pharmaceuticals (California U.S)•              Currax Pharmaceuticals LLC (New Jersey, U.S)•              Pfizer Inc. (New York, U.S)•              F. Hoffmann-La Roche Ltd (Basel, Switzerland)•              Other Players
Presence of Prominent Enterprises to Help North America DominateNorth America is set to dominate the global anti-obesity drugs market with a value of USD 964.8 million in 2019. The presence of the majority of key players in the U.S. is anticipated to drive the demand for drugs in the region. In addition, rising instances of obesity among the population in the U.S. are compelling people to adopt weight management consulting, which is estimated to further surge the demand for anti-obesity drugs in the region. For instance, as per the Harvard Medical School, the rate of obesity has increased by more than 50% in less than 40 years.The market in Europe is projected to showcase a positive growth during the forecast period. High investments in research for the development of therapeutically effective drugs, along with increasing awareness regarding the benefits of weight management among the population are key factors accelerating the demand for these drugs in the region.
Click here to get the short-term and long-term impacts of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783
Industry Developments-In December 2020, the U.S. Food and Drug Administration (FDA) approved Saxenda, Novo Nordisk’s anti-obesity drug for the treatment of obesity in adolescents aged 12-17.In February 2019, Eisai Inc. announced that the U.S. Food and Drug Administration (FDA) had accepted its new supplemental drug application. This will update the labeling of BELVIQ, the company’s anti-obesity drug.
Quick Buy –  Anti-obesity Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104783
Acquisition Strategies to Aid Key Players Expand their Product PortfoliosProminent players operating in the global anti-obesity drugs market are focusing on various acquisition strategies in order to expand their businesses. This will also help them strengthen their portfolios. For instance, in September 2019, Currax Pharmaceutical acquired Nalpropion Pharmaceuticals, which helped the company add Contrave anti-obesity medication in its product portfolio.Some major points from Table of Content:IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsNew Type LaunchPipeline AnalysisPrevalence of Obesity – By Key Countries/RegionImpact of COVID-19 on the Global Anti-obesity Drugs MarketOverview of Trends in the Anti-obesity MarketKey Industry Developments – Mergers, Acquisitions, and PartnershipsGlobal Anti-obesity Drugs Market Analysis, Insights and Forecast, 2016-2027Key Findings / SummaryMarket Analysis, Insights and Forecast – By TypePrescription DrugsOTC DrugsMarket Analysis, Insights and Forecast – By Distribution ChannelHospital PharmacyRetail PharmacyOnline PharmacyMarket Analysis, Insights and Forecast – By GeographyNorth AmericaEuropeAsia pacificLatin AmericaMiddle East & AfricaTOC Continued..!
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/anti-obesity-drugs-market-104783
Anti-obesity Drugs Market Segments Covered in the ReportBy TypePrescription DrugsOTC DrugsBy Distribution ChannelHospital PharmacyRetail PharmacyOnline Pharmacy
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/anti-obesity-drugs-market-104783
Have a Look at Related Reports:Neurovascular Devices/ Interventional Neurology Market Size, Share & Industry Analysis, By Device Type (Stenting Systems, Embolization, Neurothrombectomy and Support Devices), By Application (Cerebral Aneurysms, Ischemic Stroke and Others), By End User (Hospitals, Specialty Clinics and Others) and Regional Forecast, 2019-2026Next-Generation Sequencing (NGS) Market Size, Share and Industry Analysis By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Regional Forecast, 2019 – 2026Biomarkers Market Size, Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026Infusion Pump Market Size, Share & Industry Analysis, By Type (Volumetric Pumps, Syringe Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Implantable Pumps, and PCA Pumps), By Application (Diabetes, Oncology, Pain Management, and Others), By End User (Hospitals & Clinics, Ambulatory Care Settings, Home Care Settings, and Others), and Regional Forecast, 2019-2026Active Pharmaceutical Ingredient (API) Market Size, Share & Industry Analysis, By Type (Generic API, and Branded API), By Synthesis (Biological API, and Synthetic API), and Regional Forecast, 2019-2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/global-anti-obesity-drugs-market-10520

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.